EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Real-world comparative outcomes and toxicities after definitive radiotherapy using proton beam therapy versus intensity-modulated radiation therapy for prostate cancer: a retrospective, single-institutional analysis

Yojiro Ishikawa, Motohisa Suzuki, Hisashi Yamaguchi, Ichiro Seto, Masanori Machida, Yoshiaki Takagawa, Yusuke Azami, Yuntao Dai, Nor Shazrina Sulaiman, Satoshi Teramura, Yuki Narita, Takahiro Kato und 3 weitere

Journal of Radiation Research · 2025

DOI: 10.1093/jrr/rrae065 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Radiation Research, 2025. Verfasst von Yojiro Ishikawa und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Southern Tohoku Proton Therapy Center 7-172, Yatsuyamada, Koriyama, Fukushima 963-8052, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Proton Therapy, Radiotherapy, Intensity-Modulated. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This retrospective study aimed to compare the clinical outcomes of intensity-modulated radiation therapy (IMRT) and proton beam therapy (PBT). A total of 606 patients diagnosed with prostate cancer between January 2008 and December 2018 were included. Of these patients, 510 received PBT up to a dose of 70–78 Gy (relative biological effectiveness) and 96 patients received IMRT up to a dose of 70–78 Gy. The median follow-up period was 82 months (range: 32–140 months). Patients in the PBT group had significantly higher 7-year rates of biochemical relapse-free survival (bRFS) and disease-free survival (DFS) rates: 95.1% for PBT vs 89.9% for IMRT (P = 0.0271) and 93.1% for PBT vs 85.0% for IMRT (P = 0.0019). After matching analysis, 94 patients were assigned to both groups, and the PBT group showed significantly higher 7-year bRFS and DFS rates: 98.9% for PBT vs 89.7% for IMRT (P = 0.023) and 93.4% for PBT vs 84.6% for IMRT (P = 0.022), respectively. In the subgroup analysis of intermediate-risk patients, the PBT group showed a significantly higher 7-year bRFS rate (98.3% for PBT vs 90.5% for IMRT; P = 0.007). The V60 of the bladder in the PBT group (18.1% ± 10.1%) was higher than that in the IMRT group (14.4% ± 7.6%) (P = 0.024). This study found that the treatment outcomes of PBT potentially surpassed those of IMRT specifically concerning bRFS and DFS in real-world settings. However, it should be noted that attention is warranted for late bladder complication of PBT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsProton TherapyRadiotherapy, Intensity-ModulatedHumansMaleRetrospective StudiesAgedMiddle AgedTreatment OutcomeAged, 80 and overDisease-Free SurvivalRadiotherapy Dosage

Stichwörter der Autor:innen

biochemical recurrencebiochemical relapse-free survivalintensity-modulated radiation therapyprostate cancerproton beam therapy

Autor:innen und Institutionen

  • Department of Radiation Oncology, Southern Tohoku Proton Therapy Center 7-172, Yatsuyamada, Koriyama, Fukushima 963-8052, Japan.
  • Division of Radiology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, 1-15-1 Fukumuro, Miyagino-ku, Sendai, Miyagi 983-8536, Japan.
  • Department of Minimally Invasive Surgical and Medical Oncology, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1295, Japan.
  • Department of Radiological Sciences, School of Health Sciences, Fukushima Medical University, 1 Hikariga-oka, Fukushima 960-1295, Japan.
  • Department of Urology, Southern Tohoku Hospital, 7-172 Yatsuyamada, Koriyama, Fukushima 963-8052, Japan.

Zitieren

APA

Ishikawa, Y., Suzuki, M., Yamaguchi, H., Seto, I., Machida, M., Takagawa, Y., Azami, Y., Dai, Y., Sulaiman, N. S., Teramura, S., Narita, Y., Kato, T., Kikuchi, Y., Fukaya, Y., & Murakami, M. (2025). Real-world comparative outcomes and toxicities after definitive radiotherapy using proton beam therapy versus intensity-modulated radiation therapy for prostate cancer: a retrospective, single-institutional analysis. Journal of Radiation Research. https://doi.org/10.1093/jrr/rrae065

Vancouver

Ishikawa Y, Suzuki M, Yamaguchi H, Seto I, Machida M, Takagawa Y, et al. Real-world comparative outcomes and toxicities after definitive radiotherapy using proton beam therapy versus intensity-modulated radiation therapy for prostate cancer: a retrospective, single-institutional analysis. Journal of Radiation Research. 2025. doi:10.1093/jrr/rrae065

BibTeX
@article{Ishikawa2025,
  author = {Ishikawa, Yojiro and Suzuki, Motohisa and Yamaguchi, Hisashi and Seto, Ichiro and Machida, Masanori and Takagawa, Yoshiaki and Azami, Yusuke and Dai, Yuntao and Sulaiman, Nor Shazrina and Teramura, Satoshi and Narita, Yuki and Kato, Takahiro and Kikuchi, Yasuyuki and Fukaya, Yasuo and Murakami, Masao},
  title = {Real-world comparative outcomes and toxicities after definitive radiotherapy using proton beam therapy versus intensity-modulated radiation therapy for prostate cancer: a retrospective, single-institutional analysis},
  journal = {Journal of Radiation Research},
  year = {2025},
  doi = {10.1093/jrr/rrae065}
}
Kostenlos starten →